6 unknown, 5 recruiting, 3 completed, 2 active not recruiting. 17 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 17 | Unknown 6, Recruiting 5, Completed 3, Active not recruiting 2, Terminated 1 |
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-12-30 | 2026-04-27 |
| Safety and Efficacy of PRG-2302 for Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia Disease. PRG2302 - Acute Lymphoblastic Leukemia | Early Phase 1 | Recruiting | Tan Jie | 18 | 2024-05-24 | 2024-10-26 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research Metabolically Armed CD19 CAR-T cells - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Unknown | The Children's Hospital of Zhejiang University School of Medicine | 36 | 2024-05-15 | 2024-05-01 |
| Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia Levocarnitine - Acute Lymphoblastic Leukemia, Hepatotoxicity | Early Phase 1 | Unknown | Children's Hospital of Orange County | 20 | 2023-03-03 | 2024-08-21 |
| Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies allogenic CD19-CAR-NK cells - Acute Lymphoblastic Leukemia, B-cell Lymphoma | Early Phase 1 | Unknown | Xuzhou Medical University | 12 | 2023-03-01 | 2023-02-22 |
| Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research Metabolically Armed CD19 CAR-T cells - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Unknown | Anhui Provincial Hospital | 18 | 2023-02-10 | 2024-02-26 |
| A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Venetoclax - Acute Lymphoblastic Leukemia | Early Phase 1 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 12 | 2022-06-16 | 2026-06-16 |
| A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies CTA30X - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Completed | He Huang | 3 | 2020-12-29 | 2025-01-24 |
| A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies CAR-T cells, Ommaya Reservoir - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Early Phase 1 | Recruiting | Zhejiang University | 72 | 2020-11-01 | 2020-10-26 |
| A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies Murine CD19 CAR-T cells - Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma of Soft Tissue | Early Phase 1 | Recruiting | Zhejiang University | 120 | 2020-11-01 | 2020-10-26 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission | Early Phase 1 | Terminated | Rutgers, The State University of New Jersey | 2 | 2020-10-26 | 2023-06-26 |
| A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL Humanized CD19 CAR-T cells - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | Early Phase 1 | Unknown | Zhejiang University | 72 | 2020-08-23 | 2020-08-31 |
| A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy CT-RD06 - Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | Early Phase 1 | Unknown | He Huang | 72 | 2020-02-05 | 2020-02-21 |
| A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy CTA101 - Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | Early Phase 1 | Recruiting | He Huang | 72 | 2020-01-08 | 2020-12-28 |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy Biospecimen Collection, Dual-Energy Computed Tomography, Fluorothymidine F-18 - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Early Phase 1 | Active not recruiting | City of Hope Medical Center | 82 | 2018-02-15 | 2026-06-08 |
| Intra-Osseous Co-Transplant of UCB and hMSC cyclophosphamide, fludarabine phosphate, total-body irradiation - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 6 | 2015-07-22 | 2020-12-04 |
| A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy Hyper-CVAD, Sirolimus - Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 7 | 2010-07-01 | 2025-05-04 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (17) · Lymphoma, Non-Hodgkin (10) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Mantle-Cell (2) · Myelodysplastic Syndromes (2) · Burkitt Lymphoma (1) · Chromosome 17 deletion (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, T-Cell (1) · Multiple Myeloma (1)
Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Leukemia (17) · Leukemia, Lymphoid (17) · Lymphatic Diseases (17) · Lymphoproliferative Disorders (17) · Neoplasms by Histologic Type (17) · Neoplasms (16) · Lymphoma (12) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Disease Attributes (3) · Bone Marrow Diseases (2)
Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · Biopsy (1) · CVAD protocol (1) · Carnitine (1) · Cord Blood Stem Cell Transplantation (1) · Cyclosporine (1) · Doxorubicin (1) · Immunotherapy, Adoptive (1) · Leukapheresis (1) · Mesenchymal Stem Cell Transplantation (1) · Methotrexate (1) · Mycophenolic Acid (1) · Phantoms, Imaging (1) · Sirolimus (1)
He Huang (3) · Zhejiang University (3) · City of Hope Medical Center (2) · Anhui Provincial Hospital (1) · Case Comprehensive Cancer Center (1) · Children's Hospital of Orange County (1) · Memorial Sloan Kettering Cancer Center (1) · Rutgers, The State University of New Jersey (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Tan Jie (1) · The Children's Hospital of Zhejiang University School of Medicine (1) · Xuzhou Medical University (1)
China (10) · United States (7)
Ibrahim Aldoss (1) · Jae Park, MD (1) · Jeffrey Y Wong (1) · Kailin Xu, M.D., Ph.D. (1) · Leland Metheny, MD (1) · Margaret Kasner, MD (1) · Roger Strair (1)
PMID 36808074, PMID 37192741, PMID 42040934
P30CA033572 (2), P30CA043703 (1), P30CA072720 (1)